ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan

ImCheck secures substantial non-dilutive funding to accelerate the progress of two breakthrough programs in cancer and infectious diseases, in support of France's 2030 ambitious vision to deliver 20 innovative biomedicines by the end of the decade.

Marseille, France, August 29, 2024, 11 am CET – ImCheck Therapeutics announced today that it has received EUR 20.18 million in non-dilutive funding as part of the “i-Démo” call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government.

The funding will support the development of the company’s most advanced drug candidate, ICT01, a pathogen-agnostic γ9δ2 T cell-activating monoclonal antibody, currently in a Phase I/IIa clinical trial program in various solid cancer and hematologic malignancy indications.  The funding also supports ImCheck’s ICT41 infectious disease candidate, which is moving toward clinical development.

“We are honored to be supported by the France 2030 innovation plan. It is a tribute to theprogress we have achieved in the clinic and the overall potential of our novel immunotherapeutic programs. Our approach is both unique and polyvalent, enabling us to address solid tumors, hematologic malignancies and infectious diseases. This recognition from the French government and Bpifrance represents their confidence in our first-in-class therapies, which have the potential to significantly improve patients’ lives,” commented Pierre d’Epenoux, Chief Executive Officer of ImCheck Therapeutics. “We look forward to providing updates from the ICT01 clinical development program as well as other corporate advances later this year.”

• _{Download the pdf to read the full PR}